OSE Immunotherapeutics enters commercial and revenue sharing agreement with MSK in the field of CAR T-cell therapies

MLA

“OSE Immunotherapeutics Enters Commercial and Revenue Sharing Agreement with MSK in the Field of CAR T-Cell Therapies.” PharmaBiz, June 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.798857524&authtype=sso&custid=ns315887.

APA

OSE Immunotherapeutics enters commercial and revenue sharing agreement with MSK in the field of CAR T-cell therapies. (2024, June 25). PharmaBiz.

Chicago

PharmaBiz. 2024. “OSE Immunotherapeutics Enters Commercial and Revenue Sharing Agreement with MSK in the Field of CAR T-Cell Therapies,” June 25. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.798857524&authtype=sso&custid=ns315887.